ERBB2 and ductal breast carcinoma in situ: HER2 testing is not routinely done on DCIS cases, as anti-HER2 therapies are not employed, but the proportion reported in DCIS is consistently higher than IBC, ranging 18–56% with higher rates in high-grade DCIS, depending on the cohort (22, 25, 56, 72, 73).